Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.475
Bid: 1.45
Ask: 1.50
Change: 0.025 (1.72%)
Spread: 0.05 (3.448%)
Open: 1.475
High: 1.50
Low: 1.45
Prev. Close: 1.45
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

Wed, 03rd Apr 2024 10:47

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Genedrive PLC, up 57% at 5.90 pence, 12-month range 2.56p-34.90p. The molecular diagnostics company announces that the UK's National Institute for Health & Care Excellence has recommended in draft guidance that Genedrive's CYP2C19-ID test should be used as the point-of-care test of choice for ischemic stroke and transient ischaemic attack patients. Chief Executive Officer James Cheek comments: "We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for face, arms, speech and time, and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect....With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve US Food & Drug Administration approval and sales being realised from new customers in 2024 we feel there is growing momentum within the group's POC pharmacogenetic testing strategy."

----------

Corero Network Security PLC, up 15% at 10.36p, 12-month range 5.50p-10.65p. The cybersecurity provider specialising in distributed denial-of-service protection solutions wins a contract renewal worth over USD2 million over three years with an unnamed US-based software-as-a-service provider, expanding its partnership and marking one of Corero's "largest" single transactions to date. Corero says the deal reinforces its strong customer retention track record, while "significantly" enhancing the customer's distributed denial-of-service protection infrastructure. This ensure the "security and service availability of the SaaS provider's worldwide operations and reinforcing its resilience against the burgeoning range of cyberthreats". Corero Chief Executive Officer Carl Herberger comments: "We are committed to providing cutting-edge, reliable DDoS protection solutions to support our customers' growth and operational security and will continue to explore new business and mandate expansion opportunities as we aim to both broaden and strengthen our client portfolio."

----------

AIM - LOSERS

----------

Peel Hunt Ltd, down 5.1% at 120.00p, 12-month range 78.00p-142.00p. The investment bank expects a full-year loss as increasing costs offset a modest rise in revenue. In a trading statement for the year to March 31, Peel Hunt says revenue is expected to be consistent with market expectations at around GBP85.5 million, up 3.9% from GBP82.3 million last year. This growth comes despite equity capital markets "remaining challenging" throughout the financial year. Looking ahead, the firm expects market trading volumes to remain low until there are meaningful signs of recovery in the UK economy and fund outflows reverse. It notes whilst initial public offering activity in the UK remains muted, there has been more activity in Europe and sentiment towards IPOs is improving in the UK, with investors increasingly willing to engage in relation to high quality companies.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 Oct 2019 11:59

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

Read more
3 Oct 2019 11:00

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Read more
3 Oct 2019 10:41

Genedrive loss narrowed after double-digit revenue rise

(Sharecast News) - Genedrive on Thursday reported a narrowed annual loss as revenues jumped as its commercial relationship with the US department of defense (DoD) exceeded expectations.

Read more
9 Jul 2019 10:54

Genedrive Revenue To Suffer On Lower Uptake Of Hepatitis Test Kits

(Alliance News) - Shares in Genedrive PLC fell Tuesday after the company warned that it will miss market expectations for 2020 financial year revenue due to slower than expected uptake of the HCV

Read more
28 Mar 2019 10:36

Genedrive Interim Loss Narrows As It Continues Focus On Hepatitis

LONDON (Alliance News) - Genedrive PLC on Thursday reported a reduction in its interim loss, as it continues to progress its hepatitis testing product.For the six months to the end of 2018,

Read more
28 Mar 2019 07:59

Genedrive losses narrow despite increased R&D costs

(Sharecast News) - Molecular diagnostics company Genedrive saw revenues tick ahead slightly in the first half of its financial year but increased research and development costs kept the firm in the red.

Read more
15 Jan 2019 12:44

Genedrive Interim Revenue Rises On US And UK Government Contracts

LONDON (Alliance News) - Genedrive PLC said Tuesday it increased its first-half income and made "good progress" on two UK government funded projects.For the six months to the end

Read more
15 Jan 2019 10:17

Genedrive makes progress with HCV kit in first half

(Sharecast News) - Near-patient molecular diagnostics company Genedrive issued an unaudited update for the six months ended 31 December on Tuesday, reporting revenue of £1.5m, up from £1.3m year-on-year.

Read more
10 Dec 2018 16:23

BGF Investment Management Now Owns 12.8% Stake In Genedrive (ALLISS)

LONDON (Alliance News) - Genedrive PLC said Monday that BGF Investment Management Ltd now owns a 12.8% stake in the company.BGF's stake in the firm prior to Monday's deal, if any,

Read more
29 Nov 2018 13:56

Genedrive To Participate In Study For Use Of HCV Assay In Pharmacies

LONDON (Alliance News) - Genedrive PLC on Thursday said it will participate in an international multicentre trial to assess the impact of out-reach HCV diagnostics and therapy in a pharmacy versus

Read more
29 Nov 2018 11:49

Genedrive to participate in three-country HCV therapy study

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Thursday that it will participate in an international multicentre trial, designed to assess the impact of outreach HCV diagnostics and therapy in a pharmacy setting when compared conventional treatment pathways.

Read more
22 Aug 2018 11:17

Genedrive Appoints Chris Yates As Non-Executive Director

LONDON (Alliance News) - Diagnostics company Genedrive PLC said Wednesday it appointed Chris Yates as non-executive director with immediate effect.Yates has been Chief Executive Officer of

Read more
8 Aug 2018 12:05

Genedrive Partners With FIND To Evaluate Its Hepatitis C Virus Kit

LONDON (Alliance News) - Genedrive PLC said Wednesday it partnered with the Foundation for Innovation of New Diagnostics, or FIND, which will evaluate its hepatitis C virus kit.The kit is a

Read more
20 Jun 2018 09:57

Genedrive Given Grant For NHS Point-Of-Care Test Development

LONDON (Alliance News) - Genedrive PLC's said Wednesday it was awarded a multi-partner grant to develop a pharmacogenetic test to fight antibiotic-related hearing loss in newborn molecular was

Read more
14 May 2018 18:07

Genedrive To Sell Two Divisions For Up To GBP1.9 Million In Cash

LONDON (Alliance News) - Genedrive PLC said Monday it proposed the disposal of the its contract research and pharmacogenomics divisions for up to GBP1.9 million in cash to biotechnology company 2

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.